Biofrontera BFRI
NASDAQ BFRI
$0.81 +0.01 (+1.54%)
As of: Oct 22, 2026 · 2:22 PM EDT

Biofrontera (BFRI) Short-Term Debt issuances (2023)

Updated

Biofrontera (BFRI) reported Short-Term Debt issuances of $7.9 million for Q4 2023, up 0.7% from the prior quarter.

Analysis

Biofrontera (BFRI) Short-Term Debt issuances (2023) Analysis & Trends

For FY2023, Biofrontera posted Short-Term Debt issuances of $21.45 million.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ST Debt Issuance (Qtr)
1 Eli Lilly 1,171.69 Bn 1,140.28 Bn 19.71 Bn -
2 Johnson & Johnson 649.22 Bn 569.08 Bn 17.30 Bn 2.28 Bn
3 AbbVie 504.17 Bn 477.29 Bn 12.70 Bn -
4 Merck 366.35 Bn 320.73 Bn 12.21 Bn -
5 Novartis Ag 303.54 Bn 267.53 Bn 11.24 Bn -
6 Astrazeneca 269.49 Bn 243.18 Bn 12.86 Bn -
7 Amgen 242.61 Bn 198.01 Bn 7.24 Bn -
8 Gilead Sciences 195.09 Bn 169.29 Bn 6.22 Bn -
9 Pfizer 172.48 Bn 119.12 Bn 10.94 Bn -
10 Biofrontera 10.50 Mn -11.29 Mn 9.59 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2023 11.70 Mn
Sep 30, 2023 7.85 Mn
API Access

Biofrontera Short-Term Debt issuances API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=short-term-debt-issuances&ticker=BFRI&period=max&api_key=YOUR_API_KEY